+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 42 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.

Age: 18Years +All GendersPhase 3
87 locations
P

Actively Recruiting

Researchers are evaluating the tolerability of OJP-001, a combined therapeutic system that includes photodynamic therapy with OMD-001 and extracorporeal circulation therapies OJE-001 and OJC-001, in patients with adult T-cell leukemialymphoma ATL. The study also aims to find the recommended dose and study the way OMD-001 moves through the body, along with assessing the safety and effectiveness of OJP-001. This is a Phase III clinical trial sponsored by Otsuka Medical Devices Co., Ltd. Japan. In the Phase I part, patients receive a single oral dose of 5-ALA followed by one administration of OJP-001. The 5-ALA dose is increased across four groups from 10 mgkg up to 60 mgkg. In the Phase II part, patients receive both 5-ALA and OJP-001 once a week for six months. The treatment involves the use of a photodynamic system combined with 5-ALA, administered according to the defined dosing schedules. Participants will undergo safety and response evaluations during the first two weeks for Phase I and over 24 weeks for Phase II. The main outcomes measured include dose-limiting toxicities in Phase I and best overall response in Phase II. The study involves monitoring blood levels, physical status, and other health markers to assess treatment effects and safety. Total participation may extend up to six months during the Phase II treatment period.

Age: 20Years - 85YearsAll GendersPhase 1Phase 2
5 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.

Age: 18Years +All GendersPhase 3
132 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
O

Actively Recruiting

Researchers are evaluating the effect of nipocalimab on total serum immunoglobulin G IgG in children and adolescents aged 2 to less than 18 years with generalized myasthenia gravis gMG who have an insufficient response to stable standard therapy. The study also assesses the safety, tolerability, and pharmacokinetics of nipocalimab in this pediatric population. Participants are grouped by age into children 2 to less than 12 years and adolescents 12 to less than 18 years. Participants receive nipocalimab as an intravenous infusion once every two weeks for 24 weeks. After this treatment period, they have the option to join a long-term extension phase. The study is open-label and uncontrolled, focusing on assessing pharmacokinetics, pharmacodynamics, safety, and activity of nipocalimab in children and adolescents with gMG. Throughout the study, participants undergo monitoring for changes in serum IgG levels and evaluations of adverse events, laboratory tests, vital signs, and physical examinations up to three years. Researchers also assess neurological function and quality of life measures using standardized tools. Blood samples are collected to evaluate drug concentration and immune response. Safety and tolerability are closely monitored during and after treatment, with the entire participation lasting up to three years.

Age: 2Years - 17YearsAll GendersPhase 2Phase 3
19 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
O

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral nuvisertib TP-3654 in patients with intermediate or high-risk primary or secondary myelofibrosis. This Phase 12, multicenter, open-label trial includes patients who have previously been treated with JAK inhibitors or are ineligible for such treatments. The study aims to understand nuvisertibs effects in different patient groups based on prior treatment history and current medication use. Participants are assigned to one of three groups nuvisertib alone for those intolerant or resistant to JAK inhibitors nuvisertib added to stable doses of ruxolitinib for patients with lost or suboptimal response or nuvisertib combined with momelotinib for those previously treated with a JAK inhibitor other than momelotinib. Treatments are given orally, with dosing adjusted through dose escalation phases. The study monitors patients from initial treatment through ongoing assessment periods. Throughout the trial, participants undergo evaluations including spleen volume measurement by MRI or CT, symptom scoring using the Myelofibrosis Symptom Assessment Form, and monitoring for adverse events. Researchers track dose-limiting toxicities and treatment-emergent adverse events, as well as pharmacokinetic parameters like drug concentration and half-life. The study also assesses changes in symptoms and spleen size over time. Participation may last several months, with regular visits for assessments and safety monitoring until the studys completion.

Age: 18Years +All GendersPhase 1Phase 2
91 locations

1-10 of 42

1